AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33200660 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced scanning parameters for DPT (60 kV, 3.2 mA) and LC (85 kV, 8 mA)
Number of subjects: 38
Study 33200660 — intervention group
Group type: COMPARATOR
Intervention: Standard scanning parameters as prescribed by the manufacturer
Number of subjects: 38
Study 33200660 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced scanning parameters for DPT and LC
Number of subjects: 38
Study 33611729 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 17
Study 33611729 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic hypothermia (control group)
Number of subjects: 17
Study 35618446 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein shot (15 g of protein)
Number of subjects: 18
Study 35618446 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 18
Study 34419058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid electric fields (EFs)
Number of subjects: 203
Study 34419058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion current exposure
Number of subjects: 203
Study 34419058 — intervention group
Group type: EXPERIMENTAL
Intervention: High relative humidity
Number of subjects: 203
Study 34419058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low relative humidity
Number of subjects: 203
Study 35420921 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT
Number of subjects: 1150
Study 35420921 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1150
Study 33486770 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/ml oligomer chitosan solution
Number of subjects: 24
Study 33486770 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/ml oligomer chitosan solution
Number of subjects: 24
Study 33486770 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/ml 30 kDa chitosan solution
Number of subjects: 24
Study 33486770 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/ml 30 kDa chitosan solution
Number of subjects: 24
Study 33486770 — intervention group
Group type: COMPARATOR
Intervention: 0.1% acetic acid
Number of subjects: 24
Study 33486770 — intervention group
Group type: COMPARATOR
Intervention: 0.2% acetic acid
Number of subjects: 24
Study 33486770 — intervention group
Group type: COMPARATOR
Intervention: Effervescent tablet (Polident)
Number of subjects: 24
Study 33486770 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 24
Study 33089454 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position (group RT)
Number of subjects: 79
Study 33089454 — intervention group
Group type: COMPARATOR
Intervention: Supine position (group S)
Number of subjects: 79
Study 32013621 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Occupational Therapy (EOT)
Number of subjects: 0
Study 32013621 — intervention group
Group type: COMPARATOR
Intervention: Standard Rehabilitation (SR)
Number of subjects: 0
Study 37179154 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital scanning
Number of subjects: 40
Study 37179154 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 40
Study 37179154 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Index Score (CIS)
Number of subjects: 40
Study 37179154 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP-14 scores
Number of subjects: 40
Study 33948951 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel scaffold treatment (n = 5)
Number of subjects: 5
Study 33948951 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (n = 5)
Number of subjects: 5
Study 32173950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Adherence Programme (TAP)
Number of subjects: 183
Study 32173950 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 183
Study 36480798 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 270
Study 36480798 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 270
Study 36480798 — intervention group
Group type: COMPARATOR
Intervention: DCB and POBA
Number of subjects: 270
Study 34448111 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention (10 sessions) provided as a supplement to Early Head Start (EHS)
Number of subjects: 0
Study 34448111 — intervention group
Group type: COMPARATOR
Intervention: Control group received home-based EHS plus 1 book per week for 10 weeks
Number of subjects: 0
Study 35354455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride + acetic acid (GFAA)
Number of subjects: 40
Study 35354455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride + gastric acid (GFGA)
Number of subjects: 40
Study 35354455 — intervention group
Group type: COMPARATOR
Intervention: Saliva (Gs)
Number of subjects: 40
Study 35354455 — intervention group
Group type: COMPARATOR
Intervention: Gastric acid (GGA)
Number of subjects: 40
Study 35354455 — intervention group
Group type: COMPARATOR
Intervention: Acetic acid (GAA)
Number of subjects: 40
Study 35354455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitabloc Mark II CAD (GFAA and GFGA)
Number of subjects: 40
Study 32347768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT) for patients with disease confined to the uterus, >=50% myometrial invasion (MI) and/or grade 3 histology.
Number of subjects: 683
Study 32347768 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)+/‐VBT for patients with stage II disease, positive/close surgical margins or extra‐uterine extension.
Number of subjects: 683
Study 32347768 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IB - grade 3 and stage II in HR patients.
Number of subjects: 683
Study 32347768 — intervention group
Group type: EXPERIMENTAL
Intervention: Current risk grouping recommended by ESMO‐ESGO‐ESTRO.
Number of subjects: 683
Study 32790718 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care (SC)
Number of subjects: 128
Study 32790718 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 128
Study 33818277 — intervention group
Group type: EXPERIMENTAL
Intervention: On-axis measurements of axial length (AL) using Lenstar LS 900 biometer
Number of subjects: 207
Study 33818277 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-axis measurements of axial length (AL) in paracentral positions (temporal, superior, inferior, nasal) using Lenstar LS 900 biometer
Number of subjects: 207
Study 33818277 — intervention group
Group type: COMPARATOR
Intervention: Comparison of superior and nasal AL to central AL
Number of subjects: 207
Study 34703055 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pectoral nerve block (30 ml of ropivacaine 0.2%)
Number of subjects: 50
Study 34703055 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (no block)
Number of subjects: 50
Study 36137599 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical management (BMM) combined with endovascular therapy
Number of subjects: 0
Study 36137599 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (BMM) alone
Number of subjects: 0
Study 35018550 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted means based approach
Number of subjects: 0
Study 35018550 — intervention group
Group type: COMPARATOR
Intervention: Parametric and nonparametric competitors
Number of subjects: 0
Study 32747417 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 149
Study 32747417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 34582624 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 79
Study 34582624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 32779223 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System information and support services (CHESS‐IS)
Number of subjects: 326
Study 32779223 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS with mentor
Number of subjects: 326
Study 32779223 — intervention group
Group type: COMPARATOR
Intervention: Internet only
Number of subjects: 326
Study 35805627 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 Intermittent Fasting (IF)
Number of subjects: 34
Study 35805627 — intervention group
Group type: COMPARATOR
Intervention: Supervised Sprint Interval Training (SIT)
Number of subjects: 34
Study 35805627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IF and SIT
Number of subjects: 34
Study 35805627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone or with IF
Number of subjects: 34
Study 34387258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape sealing of face masks
Number of subjects: 13
Study 34387258 — intervention group
Group type: COMPARATOR
Intervention: No tape sealing (control)
Number of subjects: 13
Study 34052947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 53
Study 34052947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (in patients with no Helicobacter pylori infection)
Number of subjects: 53
Study 34052947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 33827457 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusional kurtosis imaging (DKI)
Number of subjects: 110
Study 33186740 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib (4 mg) plus fulvestrant (500 mg)
Number of subjects: 516
Study 33186740 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg)
Number of subjects: 516
Study 32305272 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Blood Culture Identification (BCID) panel
Number of subjects: 100
Study 36370124 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (add-on treatment)
Number of subjects: 95
Study 36370124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control treatment)
Number of subjects: 95
Study 33972742 — intervention group
Group type: EXPERIMENTAL
Intervention: tepotinib (500 mg once daily)
Number of subjects: 90
Study 33972742 — intervention group
Group type: COMPARATOR
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 90
Study 33972742 — intervention group
Group type: EXPERIMENTAL
Intervention: tepotinib
Number of subjects: 90
Study 33972742 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 90
Study 32366288 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 128
Study 32366288 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 128
Study 33471486 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message navigation (SMS)
Number of subjects: 1625
Study 33471486 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1625
Study 34003685 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based application for monitoring blood pressure
Number of subjects: 7394
Study 34003685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control group
Number of subjects: 7394
Study 34003685 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BP control group
Number of subjects: 7394
Study 34003685 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug regimen change
Number of subjects: 7394
Study 34003685 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring BP via smartphone app
Number of subjects: 7394
Study 34003685 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor monitoring of BP via app
Number of subjects: 7394
Study 33206626 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone foam dressing
Number of subjects: 50
Study 35379575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 g azithromycin orally on admission plus a third-generation cephalosporin intravenously for the first 48 hours, followed by amoxicillin 500 mg orally for another five days.
Number of subjects: 133
Study 35379575 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 133
Study 33325020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT)
Number of subjects: 24
Study 33325020 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric air (HA)
Number of subjects: 24
Study 35770525 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable electronic bronchoscope (UE-EB)
Number of subjects: 0
Study 35770525 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard bronchoscopy)
Number of subjects: 0
Study 34131487 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning support intervention
Number of subjects: 317
Study 34131487 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 317
Study 32650729 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole followed by a commercial oral/vaginal probiotic
Number of subjects: 30
Study 32650729 — intervention group
Group type: COMPARATOR
Intervention: Vaginal metronidazole alone
Number of subjects: 30
Study 35768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 105
Study 35768453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 34673771 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) titrated based on weekly assessments, mean end-dose of 1.0 mg/kg/day
Number of subjects: 207
Study 34673771 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) titrated based on weekly assessments
Number of subjects: 207
Study 32268472 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min high‐intensity (80% HRmax; HIGH) cycling exercise
Number of subjects: 13
Study 32268472 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min low‐intensity (50% HRmax; LOW) cycling exercise
Number of subjects: 13
Study 32268472 — intervention group
Group type: COMPARATOR
Intervention: 30‐min seated rest (CONTROL)
Number of subjects: 13
Study 35769160 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Bojungikgi-Tang (BJIGT)
Number of subjects: 105
Study 35769160 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose Bojungikgi-Tang (BJIGT)
Number of subjects: 105
Study 35769160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 105
Study 32217365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 104
Study 32217365 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 34562774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie-guided technique
Number of subjects: 23
Study 34562774 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 23
Study 33094359 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic cancer patients
Number of subjects: 80275
Study 33094359 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery performed on metastatic cancer patients
Number of subjects: 80275
Study 33094359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea at rest/moderate exertion
Number of subjects: 80275
Study 35654863 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloid therapy + home exercise
Number of subjects: 90
Study 35654863 — intervention group
Group type: COMPARATOR
Intervention: Paraffin therapy + home exercise
Number of subjects: 90
Study 33157048 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 823
Study 33157048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 823
Study 33157048 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint blockade
Number of subjects: 823
Study 33157048 — intervention group
Group type: COMPARATOR
Intervention: Angiogenesis blockade
Number of subjects: 823
Study 33454354 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) at cryogenic temperatures (−110 °C till −160 °C), n = 33
Number of subjects: 62
Study 33454354 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 62
Study 33454354 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled group (CG), n = 29
Number of subjects: 62
Study 33984886 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa‐carbidopa intestinal gel (LCIG) treatment
Number of subjects: 0
Study 33984886 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 36045304 — intervention group
Group type: EXPERIMENTAL
Intervention: TLPLDC vaccine
Number of subjects: 144
Study 36045304 — intervention group
Group type: COMPARATOR
Intervention: TLPLDC + G
Number of subjects: 144
Study 36045304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 34936271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongyuan acupuncture combined with medication
Number of subjects: 74
Study 34936271 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (estradiol valerate tablets, 2 mg per day from the fifth day of menstruation)
Number of subjects: 74
Study 34936271 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 74
Study 32989542 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 138
Study 32989542 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy (WLE)
Number of subjects: 138
Study 32452814 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Health Network (PHN) app with care coordination
Number of subjects: 27
Study 32452814 — intervention group
Group type: COMPARATOR
Intervention: Care coordination alone
Number of subjects: 27
Study 36339240 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin intervention (60 min × 5 times/week, 8 weeks)
Number of subjects: 54
Study 36339240 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin combined with low-carbohydrates diet (8 weeks)
Number of subjects: 54
Study 36339240 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 54
Study 36339240 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BA, LC, CON)
Number of subjects: 54
Study 32973192 — intervention group
Group type: EXPERIMENTAL
Intervention: VRN-based 3D CNN
Number of subjects: 2124
Study 32973192 — intervention group
Group type: COMPARATOR
Intervention: Clinical experts (orthopedists)
Number of subjects: 2124
Study 34135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care assessment
Number of subjects: 17
Study 34135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal care assessment
Number of subjects: 17
Study 34135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization
Number of subjects: 17
Study 34135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health service delivery score
Number of subjects: 17
Study 34135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Service provision score
Number of subjects: 17
Study 34135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility assessment score
Number of subjects: 17
Study 32783645 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Attention (FA) meditation
Number of subjects: 20
Study 32783645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Neurofeedback (mNF) meditation
Number of subjects: 20
Study 32783645 — intervention group
Group type: COMPARATOR
Intervention: Combined FA and mNF data
Number of subjects: 20
Study 35377724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 0
Study 35377724 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 0
Study 33817768 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth education interventions (synchronous, asynchronous, hybrid)
Number of subjects: 24
Study 33817768 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous eHealth education intervention
Number of subjects: 24
Study 33817768 — intervention group
Group type: COMPARATOR
Intervention: Hybrid eHealth education intervention
Number of subjects: 24
Study 36194181 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-506 at 160 mg daily for 28 days
Number of subjects: 28
Study 36194181 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-506 at 400 mg daily for 28 days
Number of subjects: 28
Study 36194181 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-506 at 400 mg daily for 28 days in Asian HS
Number of subjects: 28
Study 36194181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36194181 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-506
Number of subjects: 28
Study 33814258 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 30
Study 33814258 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 30
Study 34983475 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral central lymph node dissection (BCND)
Number of subjects: 581
Study 34983475 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral central lymph node dissection (ICND)
Number of subjects: 581
Study 33980505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C augmented trabeculectomy
Number of subjects: 453
Study 33980505 — intervention group
Group type: COMPARATOR
Intervention: Escalating medical management with intraocular pressure reducing drops
Number of subjects: 453
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol, alcohol-based hand sanitizers, povidone-iodine
Number of subjects: 0
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin, ethanol, hydroxychloroquine, quaternary ammonium compounds
Number of subjects: 0
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha, lactoferrin, hydroxychloroquine
Number of subjects: 0
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothiocyanite, N-chlorotaurine, povidone-iodine
Number of subjects: 0
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Quaternary ammonium compounds, hydroxychloroquine
Number of subjects: 0
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Quaternary ammonium compounds, alcohol-based nasal antiseptics
Number of subjects: 0
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: N-chlorotaurine
Number of subjects: 0